CNAT News 6.04 Conatus Pharmaceuticals Inc (CNAT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Conatus Pharmaceuticals Inc (CNAT) 6.04 $CNAT

Conatus Pharma Deserves a Look by Investors in Love With Liver Disease Stocks
at The Street - Wed Apr 09, 9:06AM CDT
Conatus Pharmaceuticals is an early-stage developer of drugs to treat diseases of the liver with a favorable risk-reward profile, particularly after recent investor selling in the biotech sector has created some nice values.

Company news for March 31, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 9:06AM CDT
Companies in the News are: FINL,RH,CNAT,PRGS

Conatus Pharmaceuticals Reports 2013 Financial Results and Program Updates
GlobeNewswire - Thu Mar 27, 3:12PM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the fourth quarter and full year ended December 31, 2013, and provided updates on its clinical development programs.

Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Mar 20, 3:01PM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2013, after the market close on Thursday, March 27, 2014. Conatus will host a conference call and audio webcast at 4:30 p.m. Eastern Time on Thursday, March 27, 2014, to discuss the financial results and provide a corporate update.

3 Reasons Potential Side Effects Trump Positive Phase 3 Data
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 17, 4:47PM CDT
In its 10-K on Friday, Intercept disclosed that patients with nonalcoholic steatohepatitis, or NASH, taking its liver drug obeticholic acid, or OCA experienced cardiovascular serious adverse events. On Sunday, the biotech followed up with...

New Drug Applications, Earnings Release Schedules, Drug Designations, New Services, and Clinical Trials - Analyst Notes on Actavis, Intercept, GW Pharmaceuticals, Galena, and Conatus
PR Newswire - Thu Mar 13, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), GW Pharmaceuticals plc (NASDAQ: GWPH), Galena Biopharma, Inc. (NASDAQ: GALE), and Conatus Pharmaceuticals Inc. (NASDAQ: CNAT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Fatty Liver Disease Should Keep Stocks Moving In 2014
at Investor's Business Daily - Fri Mar 07, 4:02PM CST
One of the hottest research fields in biotech is for a disease most people have never heard of. But as data on potential treatments roll out this year, it's bound to become a lot more famous on Wall Street. Non-alcoholic steatohepatitis, or NASH,...

Conatus Pharmaceuticals Extends Liver Disease Reach With Phase 2 NAFLD/NASH Trial
GlobeNewswire - Mon Mar 03, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the initiation of a Phase 2 clinical trial of its lead drug candidate, emricasan, in patients with nonalcoholic fatty liver disease (NAFLD), including the subset of NAFLD patients with inflammatory and/or fibrotic nonalcoholic steatohepatitis (NASH).

4 Big-Volume Stocks to Trade for Breakouts
at The Street - Thu Feb 27, 5:00AM CST
These stocks rising on unusual volume are within range of triggering breakout trades.

Conatus Pharmaceuticals to Participate in Upcoming Investor Events
GlobeNewswire - Thu Feb 20, 6:00AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced its scheduled participation in the following investor events in February:

Conatus Pharmaceuticals (CNAT) Soars: Stock Rises 19.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:39AM CST
Conatus Pharmaceuticals Inc. was a big mover last session, as its shares rose over 19% on the day.

Conatus Pharmaceuticals Appoints Two Additional Independent Board Members
GlobeNewswire - Mon Feb 10, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the appointment of two additional independent members to the Conatus Board of Directors: Daniel L. Kisner, M.D., a highly respected life sciences leader with demonstrated successes in drug development, pharmaceutical and research tool approvals, and venture capital investments; and Preston S. Klassen, M.D., M.H.S., an accomplished biopharmaceutical company executive with broad experience including clinical, regulatory, medical affairs and commercial responsibilities across multiple therapeutic areas.

Conatus Pharmaceuticals to Present at BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced its scheduled presentation to provide an overview of the company's programs and outlook at the Biotechnology Industry Organization (BIO) CEO & Investor Conference at 1:00 p.m. ET on Monday, February 10, 2014, in New York.

Healthcare Companies Report Petition Submission, Pricing of Follow-On Offerings and Stock Price Movements - Research Report on Johnson & Johnson, GW Pharma, Conatus Pharma, Chelsea, and Insmed
PR Newswire - Tue Jan 14, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.

Why SodaStream, Intercept Pharmaceuticals, and lululemon athletica Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Jan 13, 7:30PM CST
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Stocks didn't deliver on their bullish promise on Monday,...

Conatus Pharmaceuticals Updates Development Strategy and 2014 Milestones
GlobeNewswire - Mon Jan 13, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced plans to initiate a placebo-controlled (open to sponsor) Phase 2b clinical trial in the second half of 2014 evaluating its lead drug candidate emricasan in Post Orthotopic Liver Transplant (POLT) recipients. The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to emricasan in late 2013 for the treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end-stage liver disease. The trial will focus on the subset of POLT patients with reestablished liver fibrosis as a result of recurrent post-transplant hepatitis C virus infection who have successfully achieved a sustained viral response following HCV antiviral therapy (HCV-POLT).

516% Jump for Intercept Pharmaceuticals, Unknown Biotech With Unlikely Outcome
Brian Orelli, The Motley Fool - Motley Fool - Fri Jan 10, 5:00PM CST
Sometimes it takes big news to get a biotech on investors' radar. It doesn't get much bigger than the more than 500% jump that  Intercept Pharmaceuticals has had over the past two days. You're excused if you've never heard of Intercept...

Intercept Pharmaceuticals Inc: A Whole New Class of Blockbuster Drug Is Born
David Williamson, The Motley Fool - Motley Fool - Thu Jan 09, 6:43PM CST
Even in the volatile world of biotech investing, the idea of a stock instantly quadrupling in value is like a unicorn -- a mythological beast that investors never expect to actually see.   Well, a unicorn just showed up today, and potentially...

Nasdaq stocks posting largest percentage increases
AP - Thu Jan 09, 12:48PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:

Conatus Pharmaceuticals to Ring The NASDAQ Stock Market Opening Bell in Celebration of 2013 Milestones
GlobeNewswire - Wed Dec 18, 7:01AM CST
-- Live Webcast Available at 9:15 am ET --
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Babe Ruth Lots Lead Morphy's $2 Million Collectibles Auction

Updated Category News Views 0

Ruth still pulls money like few names ever will, and Morphy's November 10-12 auction made that plain without any circus tricks. Three lots tied to the Yankees legend produced $136,500 within a Toys, Sports & General Collectibles sale that topped $2 million. That is not some vague nostalgia story. Buyers put real dollars behind a 1932 U.S. Caramel card, a 1933 Goudey card,...

Continue Reading
CMS Audit Proposal Reopens Medicare Advantage Risk

Updated Category News Views 104

A regulator just tossed a rusted anchor into managed care's earnings model. CMS's proposed Comprehensive Regulations to Uncover Suspicious Healthcare rule, dubbed CRUSH and numbered CMS-6098-P, puts Medicare Advantage risk-adjustment audits back at center stage. The headline nobody can casually wave away: audit findings from sampled enrollees could be extrapolated across...

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 138

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading
Cybersecurity's AI Tailwind Meets a Brutal Market Test

Updated Category News Views 89

Security software caught a bid while the rest of the tape was getting kicked down the stairs. That contrast is the whole story: investors saw Palo Alto Networks deliver a strong fiscal first quarter and raise its fiscal 2027 outlook, then decided cyber defense may be one of the few technology budgets companies cannot casually postpone. With AI helping attackers locate and...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 112

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
IAS Marks 42 Years Amid Germany Religious Freedom Win

Updated Category News Views 96

Bagpipes, country roads and a gathering from six continents made this far more than a routine anniversary reception. The International Association of Scientologists marked its 42nd anniversary at Saint Hill in East Grinstead, England, with thousands of Scientologists and guests arriving as autumn settled over West Sussex. That sort of turnout is a visible statement of...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 121

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 45

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
PTC Pushes Deeper Into Federal Product Development

Updated Category News Views 82

Federal engineering software is a miserable place to show up late, and PTC is plainly trying not to. Its November 19, 2026 expansion brings Windchill+ onto Microsoft Azure Government through PTC Cloud Services and introduces Onshape Government Federal for teams handling Controlled Unclassified Information. This is not a glamorous product refresh. It is a bid to remove the...

Continue Reading
A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 130

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading

Top 5 Most Recently Viewed Articles

Projected Growth in Edge Data Center Market Through 2029

Updated Category News Views 227

Edge Data Center Market Outlook and Growth Drivers The edge data center market is set to witness impressive growth, with projections estimating an increase of USD 45.1 billion from 2025 to 2029. This surge is driven primarily by the rising demand for video streaming services and the incorporation of artificial intelligence (AI) in data center operations. Market Trends...

Continue Reading
Uncertainties Loom as U.S. Economy Reacts to Job Data Shift

Updated Category News Views 73

Economic Uncertainties Fueling Market Volatility Recent fluctuations in the U.S. economy have raised fresh concerns among investors, particularly as key employment data shows an unexpected slowdown. This situation has intensified worries about the Federal Reserve's monetary policies and the approaching U.S. presidential election season, creating a tough environment for...

Continue Reading
SME Insurance Market Expected to Surge to $45.60 Billion

Updated Category News Views 96

Growth of the SME Insurance Market Recent data shows that the global SME insurance market, currently valued at around USD 28 billion, is projected to surge to USD 45.60 billion in the coming years. This significant growth is primarily driven by the rising number of small and medium enterprises (SMEs) that need comprehensive insurance solutions to protect themselves from...

Continue Reading
Unlocking High-Yield Potential with CoinEx Dual Investment

Updated Category News Views 199

Introducing CoinEx Dual Investment CoinEx, a leading cryptocurrency exchange, has unveiled its latest offering: CoinEx Dual Investment. This innovative investment product is tailored for users seeking to maximize their returns through a unique dual-currency settlement structure. With the cryptocurrency market showing constant fluctuations, this new option empowers users...

Continue Reading
Shelby County Federal Credit Union Enhances Leadership for Growth

Updated Category News Views 160

Welcoming a New Era at Shelby County Federal Credit Union Shelby County Federal Credit Union is beginning an exciting chapter as it welcomes its newly appointed Chief Executive Officer, Raffael Crockett. With more than thirty years in the credit union sector, Crockett is renowned for his transformational leadership capabilities. His vision is set on enhancing the...

Continue Reading